SCHEMBL6722720

SCHEMBL6722720

Cc1ccc(NC(=O)C(N)c2ccccc2)cc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
ROCK2 O75116 1/20 0.56
ROCK1 Q13464 1/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
BAZ1A Q9NRL2 1/20 0.55
KMT2A Q03164 4/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
EIF2AK3 Q9NZJ5 1/20 0.54
MAPT P10636 4/20 0.52
TP53 P04637 1/20 0.52
MEN1 O00255 3/20 0.51
FKBP5 Q13451 1/20 0.51
HTT P42858 2/20 0.51
RECQL P46063 1/20 0.51
POLB P06746 1/20 0.50
AAK1 Q2M2I8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722715 1.00 ALDH1A1 (0.60) ALDH1A1ROCK2ROCK1CYP1A2CYP3A4
SCHEMBL17364128 0.88 ALDH1A1 (0.67) ALDH1A1ROCK2ROCK1BAZ1AKMT2A
SCHEMBL6820592 0.84 TAS2R14 (0.52) ALDH1A1ROCK2ROCK1CYP1A2CYP3A4
SCHEMBL6717100 0.83 ALDH1A1 (0.63) ALDH1A1ROCK2ROCK1BAZ1AKMT2A
SCHEMBL6717109 0.83 ALDH1A1 (0.63) ALDH1A1ROCK2ROCK1BAZ1AKMT2A
SCHEMBL23611205 0.82 ROCK2 (0.56) ALDH1A1ROCK2ROCK1BAZ1AKMT2A
SCHEMBL23611208 0.82 ROCK2 (0.56) ALDH1A1ROCK2ROCK1BAZ1AKMT2A
SCHEMBL12972970 0.82 KMT2A (0.51) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL6723310 0.82 HSD17B10 (0.54) ALDH1A1ROCK2ROCK1CYP1A2BAZ1A
SCHEMBL6719393 0.81 TDP1 (0.55) ALDH1A1ROCK2ROCK1BAZ1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 ALDH1A1 575/4885ROCK2 4242/4885ROCK1 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.